Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Sep 23, 2021 12:04pm
73 Views
Post# 33907629

RE:Another analyst just mailing it in

RE:Another analyst just mailing it inI can smell the Cheetos on that one...

SPCEO1 wrote: Canaccord came out with a report on the IV Push news and it just rehashed the press release and added no value. Worse, it ended with this aggregious, if unimportant, error, " Net sales of Trogarzo were $7.4M in 2Q21,representing 13% of the company’s total worldwide net sales for 2Q21."

I wish that were actually true as it would indicate TH had total second quarter sales of $57 million! It is hard to see how Ed Nash did not quickly catch this.

Once again, it is a odd error to make but insignificant. What it highlights is we need analysts covering the stock who are both very good at what they do and are fully awake while writing their research reports. Ed is pretty good at what he does but must not have had his coffee yet when writing this note. 


<< Previous
Bullboard Posts
Next >>